Literature DB >> 9790338

Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome.

G B Klintmalm1.   

Abstract

OBJECTIVE: The objective of this study from the International Registry of Hepatic Tumors in Liver Transplantation is to analyze the impact of tumor characteristics on tumor recurrence and patient survival. SUMMARY BACKGROUND DATA: Many attempts have been made to identify patients with hepatocellular carcinoma who can be treated successfully with liver transplantation. Studies presented to date lack enough patients to make reported findings universally accepted. In lieu of a prospective, randomized multicenter trial, in 1992 an International Registry of Hepatic Tumors in Liver Transplantation was established to collect data on these patients, their tumors, and their treatment.
METHODS: The registry mails out new patient registration forms and patient follow-up forms twice yearly to all known liver transplant programs. Fifty-three programs in 21 countries have supplied information on 553 patients with tumors. Four hundred ten patients had hepatocellular carcinoma (HCC), and 12 had the fibrolamellar variant of HCC (FLL-HCC). These 422 patients were investigated for this study. One hundred sixty-nine of these (40.0%) were classified as "incidental tumors." For the remaining patients, the tumor was known before the transplant. Twenty-six and eight tenths percent of the patients had a history of hepatitis B and 32.7% had a history of hepatitis C.
RESULTS: One hundred ninety patients (46.7%) have died, 99 free of tumor and 91 with tumor. Death was tumor related in 90 patients. Of the 232 patients now living, 215 are free of tumor and 17 have tumor. The most common sites for recurrence are the transplanted liver (41.7%) and the lungs (28.7%). The overall patient survival was 72.2% at 1 year, 63.4% at 2 years, 47.4% at 4 years, and 44.4% at 5 years. Using univariate analysis, incidental tumors (p = 0.3107), FLL-HCC (p = 0.0704), multifocal tumor (p = 0.5464), and bilobar tumor (p = 0.1024) were not found to have an influence on patient survival. Four factors, tumor size greater than 5 cm (p = 0.0221), vascular invasion (p = 0.0005), positive nodes (p = 0.0014), and histologic grade (p = 0.0001) had a profound impact on patient survival. Using Cox multiple regression analysis, only histologic grade had a negative impact on overall patient survival (p = 0.0009) and for patients with known tumors (p = 0.0003). For incidental tumors, patient survival was negatively influenced by multifocality (p = 0.0021) and an age older than 60 years (p = 0.0008). Tumor histologic grade (p = 0.0134) and size (>5 cm) (p = 0.0133) were significantly linked to recurrence-free patient survival.
CONCLUSIONS: This analysis has documented three tumor characteristics that strongly impact patient survival after transplantation for HCC. In addition to tumor size greater than 5 cm and the presence of vascular invasion (which confirm several, single-center studies), this registry notes that a poorly differentiated HCC may be a contraindication for transplantation. A liver tumor's histologic grade may be important information to have when these patients are considered for liver transplantation.

Entities:  

Mesh:

Year:  1998        PMID: 9790338      PMCID: PMC1191521          DOI: 10.1097/00000658-199810000-00005

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  28 in total

1.  Hepatic cryosurgery.

Authors:  T S Ravikumar; G D Steele
Journal:  Surg Clin North Am       Date:  1989-04       Impact factor: 2.741

2.  Disease recurrence following liver transplantation.

Authors:  J Hart; R W Busuttil; K J Lewin
Journal:  Am J Surg Pathol       Date:  1990       Impact factor: 6.394

Review 3.  Is liver transplantation justified for the treatment of hepatic malignancies?

Authors:  K M Olthoff; J M Millis; M H Rosove; L I Goldstein; K P Ramming; R W Busuttil
Journal:  Arch Surg       Date:  1990-10

4.  Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.

Authors:  P E Majno; R Adam; H Bismuth; D Castaing; A Ariche; J Krissat; H Perrin; D Azoulay
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

5.  The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence.

Authors:  B Ringe; C Wittekind; W O Bechstein; H Bunzendahl; R Pichlmayr
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

6.  Hepatic transplantation for primary and metastatic cancers of the liver.

Authors:  I Penn
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

7.  Primary treatment of hepatocellular carcinoma by arterial chemoembolization.

Authors:  H Bismuth; M Morino; D Sherlock; D Castaing; C Miglietta; P Cauquil; A Roche
Journal:  Am J Surg       Date:  1992-04       Impact factor: 2.565

8.  Liver transplantation for malignant disease. Results in 93 consecutive patients.

Authors:  J G O'Grady; R J Polson; K Rolles; R Y Calne; R Williams
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

9.  Is there a place for liver grafting for malignancy?

Authors:  R Pichlmayr
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

10.  Role of liver transplantation in cancer therapy.

Authors:  S Iwatsuki; R D Gordon; B W Shaw; T E Starzl
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

View more
  65 in total

Review 1.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

Review 2.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

3.  Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.

Authors:  R Tateishi; H Yoshida; S Shiina; H Imamura; K Hasegawa; T Teratani; S Obi; S Sato; Y Koike; T Fujishima; M Makuuchi; M Omata
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

4.  Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Bresson-Hadni; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Philippe Compagnon; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges-Philippe Pageaux; Sébastien Dharancy; Olivier Chazouillères; Daniel Cherqui; Christophe Duvoux
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

5.  Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma.

Authors:  Young Je Park; Do Hoon Lim; Seung Woon Paik; Kwang Cheol Koh; Joon Hyoek Lee; Moon Seok Choi; Byung Chul Yoo; Hee Rim Nam; Dong Ryul Oh; Won Park; Yong Chan Ahn; Seung Jae Huh
Journal:  J Gastroenterol       Date:  2006-12-08       Impact factor: 7.527

6.  Liver transplantation for hepatocellular carcinoma.

Authors:  A W Hemming; M S Cattral; A I Reed; W J Van Der Werf; P D Greig; R J Howard
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

7.  Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma.

Authors:  Umberto Cillo; Alessandro Vitale; Filippo Navaglia; Daniela Basso; Umberto Montin; Marco Bassanello; Francesco D'Amico; Francesco Antonio Ciarleglio; Alberto Brolese; Giacomo Zanus; Vito De Pascale; Mario Plebani; Davide Francesco D'Amico
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  Pre-liver transplant biopsy in hepatocellular carcinoma: a potential criterion for exclusion from transplantation?

Authors:  Richard S Young; Mohammed Aldiwani; Abdul R Hakeem; Amit Nair; Ashley Guthrie; Judy Wyatt; Darren Treanor; Gareth Morris-Stiff; Rebecca L Jones; K Rajendra Prasad
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

10.  Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462).

Authors:  Kiyoshi Hasegawa; Hiroshi Imamura; Masayoshi Ijichi; Yutaka Matsuyama; Keiji Sano; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Gastrointest Surg       Date:  2008-01-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.